ArticleThe Journal of clinical and aesthetic dermatology2009
Rituximab: a review of dermatological applications.
Article in The Journal of clinical and aesthetic dermatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice.Archives of dermatological research · 2024Pooled it
- Efficacy of Rituximab on Refractory Organ Involvements in Granulomatosis with Polyangiitis: A Systematic Review of Case Reports.Current rheumatology reviews · 2024Pooled it
- Increased longevity of circulating human IgG in an NSG Fc gamma receptor-1 deficient humanized mouse model.Journal of pharmaceutical sciences · 2025Article
- How Safe Are Biological Agents in Pediatric Rheumatology?Turkish archives of pediatrics · 2024Article
- Novel Therapeutic Agents for Management of Diabetes Mellitus: A Hope for Drug Designing against Diabetes Mellitus.Life (Basel, Switzerland) · 2024Review
- FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology.Annals of medicine and surgery (2012) · 2022Article
- Glutamine-free mammalian expression of recombinant glycoproteins with uniform isotope labeling: an application for NMR analysis of pharmaceutically relevant Fc glycoforms of human immunoglobulin G1.Journal of biomolecular NMR · 2022Article
- Off-Label Uses of Rituximab in Dermatology.Current dermatology reports · 2022Review
- Current Knowledge on Graves' Orbitopathy.Journal of clinical medicine · 2020Review
- Juvenile Dermatomyositis (JDM) Complicated by Thrombotic Thrombocytopenic Purpura (TTP) and Purtscher's Retinopathy Responsive to Rituximab: Case Report and Literature Review.Frontiers in pediatrics · 2020Article
- Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.Current diabetes reports · 2019Review
- Rheumatoid Arthritis: A Brief Overview of the Treatment.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2018Review
- Translational Aspects of Sphingolipid Metabolism in Renal Disorders.International journal of molecular sciences · 2017Review
- Biologics in dermatology: an integrated review.Indian journal of dermatology · 2014Review
- Review
- Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells.PeerJ · 2013Article
- Rituximab versus tacrolimus as corticosteroid-sparing therapy for children with steroid-dependent nephrotic syndrome: A systematic review and meta-analysis of randomized and nonrandomized controlled trials.Tzu chi medical journalArticle
- Biologics in Dermatology: Off-Label Indications.Indian dermatology online journalReview
- Off-label use of rituximab in dermatology: pemphigus treatment.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of many dermatological disorders, such as autoimmune and immune-mediated diseases, consists of the use of systemic corticosteroids alone or in combination with other steroid-sparing immunosuppressants. Often, these treatment regimens are sufficient to control disease activity with relatively few side effects if monitored by a diligent physician. Some patients, however, may be refractory to treatment or develop intolerable side effects from therapy. For these patients, alternative treatment modalities with less toxicity and greater efficacy are required. Rituximab is a genetically engineered, chimeric monoclonal antibody directed against the B-cell lineage specific CD20 antigen. Originally developed for the treatment of B-cell non-Hodgkin"s lymphoma, rituximab has increasingly been used to treat a variety of autoimmune and immune-mediated disorders, such as rheumatoid arthritis, pemphigus diseases, systemic lupus erythematosus, dermatomyositis, and idiopathic thrombocytopenic purpura to name a few. Since very few randomized, controlled, clinical trials exist regarding the use of rituximab in the treatment of dermatological disorders, guidelines for the off-label use of this medication come from anecdotal case reports and cohort studies. Further clinical studies are needed to validate the safety and efficacy of rituximab therapy in dermatological disorders. Until then, we present a literature review of the emerging use of this B-cell depletion therapy. (J Clin Aesthetic Dermatol. 2009;2(5):29-37.).
Identifiers
20729962PMC2924133W1528604543What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.